دورية أكاديمية
Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir.
| العنوان: | Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir. |
|---|---|
| المؤلفون: | Rath B; Charité University Medical Center, Department of Pediatrics, Berlin, Germany.; Vienna Vaccine Safety Initiative, Berlin, Germany., Chen X; Charité University Medical Center, Department of Pediatrics, Berlin, Germany., Spies V; Klinikum Worms, Department of Pediatrics and Adolescent Medicine, Worms, Germany., Muehlhans S; Charité University Medical Center, Department of Pediatrics, Berlin, Germany., Obermeier P; Charité University Medical Center, Department of Pediatrics, Berlin, Germany., Tief F; Charité University Medical Center, Department of Pediatrics, Berlin, Germany., Seeber L; Charité University Medical Center, Department of Pediatrics, Berlin, Germany., Karsch K; Charité University Medical Center, Department of Pediatrics, Berlin, Germany., Milde J; Robert Koch Institute, Division of Influenza Viruses and Other Respiratory Viruses, National Reference Centre for Influenza, Berlin, Germany., Skopnik H; Klinikum Worms, Department of Pediatrics and Adolescent Medicine, Worms, Germany., Schweiger B; Robert Koch Institute, Division of Influenza Viruses and Other Respiratory Viruses, National Reference Centre for Influenza, Berlin, Germany., Duwe SC; Robert Koch Institute, Division of Influenza Viruses and Other Respiratory Viruses, National Reference Centre for Influenza, Berlin, Germany. |
| المصدر: | Antiviral therapy [Antivir Ther] 2017; Vol. 22 (6), pp. 515-522. Date of Electronic Publication: 2017 Feb 16. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9815705 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2040-2058 (Electronic) Linking ISSN: 13596535 NLM ISO Abbreviation: Antivir Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: [London] : SAGE Publications Original Publication: London : International Medical Press |
| مواضيع طبية MeSH: | Drug Resistance, Viral* , Hospitalization*, Influenza A Virus, H3N2 Subtype/*drug effects , Influenza, Human/*drug therapy , Influenza, Human/*virology , Oseltamivir/*pharmacology , Oseltamivir/*therapeutic use, Antiviral Agents/therapeutic use ; Enzyme Inhibitors/therapeutic use ; Female ; Humans ; Infant ; Infant, Newborn ; Influenza A Virus, H3N2 Subtype/genetics ; Influenza, Human/diagnosis ; Influenza, Human/epidemiology ; Male ; Microbial Sensitivity Tests ; Neuraminidase/antagonists & inhibitors ; Public Health Surveillance ; RNA, Viral ; Viral Load |
| مستخلص: | Background: Infants exhibit elevated influenza virus loads and prolonged viral shedding, which may increase the risk for resistance development, especially in cases of suboptimal exposure to antiviral therapy. Methods: We performed a prospective surveillance of hospitalized infants undergoing oseltamivir therapy during the 2008-2009 and 2011-2012 influenza seasons at two paediatric hospitals in Germany. A total of 37 infants less than 1 year of age with laboratory confirmed influenza A(H3N2) infection received oseltamivir as per physician's order for 5 days (2008-2009 season: 2 mg/kg twice daily; 2011-2012 season: 2.0 mg/kg; 2.5 mg/kg and 3.0 mg/kg twice daily for infants <1 month; 2-3 months and 4-12 months, respectively). Virus load, the susceptibility to neuraminidase inhibitors (NAIs), and the presence of molecular markers of resistance to NAIs was assessed for influenza viruses recovered from respiratory samples collected at baseline and during follow-up visits. Results: Overall, 73% of the infants continued to shed viral RNA detectable by reverse transcription (RT)-PCR after dose number 10 of oseltamivir; 12 infants shed viruses, 2 of them (both 9 months of age) shed resistant viruses. Resistance was characterized by ≥1,000-fold increase of 50% inhibitory concentration (IC Conclusions: Our data suggest that it may be relevant to monitor antiviral resistance systematically in all infants, considering that the European Medicines Agency has recently extended the licensure for oseltamivir to include full-term infants. |
| المشرفين على المادة: | 0 (Antiviral Agents) 0 (Enzyme Inhibitors) 0 (RNA, Viral) 20O93L6F9H (Oseltamivir) EC 3.2.1.18 (Neuraminidase) |
| تواريخ الأحداث: | Date Created: 20170217 Date Completed: 20180730 Latest Revision: 20180730 |
| رمز التحديث: | 20231215 |
| DOI: | 10.3851/IMP3141 |
| PMID: | 28205506 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2040-2058 |
|---|---|
| DOI: | 10.3851/IMP3141 |